Abstract:BackgroundSperm autoantigen protein 17 (SPA17) is a highly conserved mammalian protein that participates in the acrosome reaction during fertilization and is a recently reported member of the cancer-testicular antigen (CTA) family. It has been reported that the SPA17 expression is limited in adult somatic tissues and re-expressed in tumor tissues. Recently, studies have found that SPA17 regulates the progression of various cancers, but its role in cancer immunotherapy is not clear. MethodsThe pan-cancer and normal tissue transcriptional data were acquired from The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) datasets. We explored the SPA17 pan-cancer genomic alteration analysis in the cBioPortal webtool. The Human Protein Atlas (HPA) and ComPPI websites were used to mine the SPA17 protein information. We performed a western blotting assay to validate the upregulated SPA17 expression in clinical glioblastoma (GBM) samples. The univariate Cox regression and Kaplan-Meier method were used to assess the prognostic role of SPA17 in pan-cancer. Gene Set Enrichment Analysis (GSEA) was used to search the associated cancer hallmarks with SPA17 expression in each cancer type. TIMER2.0 was the main platform to investigate the immune cell infiltrations related to SPA17 in pan-cancer. The associations between SPA17 and immunotherapy biomarkers were performed by Spearman correlation analysis. The drug sensitivity information from the Connectivity Map (CMap) dataset was downloaded to perform SAP17-specific inhibitor sensitivity analysis. FindingsSPA17 was aberrantly expressed in most cancer types and exhibited prognosis predictive ability in various cancers. In addition, our results also show that SPA17 was significantly correlated with immune-activated hallmarks (including pathways and biological processes), immune cell infiltrations, and immunoregulator expressions. The most exciting finding was that SPA17 could significantly predict anti-PDL1 and anti-PD1 therapy responses in cancer patients. Finally, specific inhibitors, like irinotecan and puromycin, which correlate with SPA17 expression in different cancer types, were also screened using Connectivity Map (CMap). ConclusionsOur results reveal that SPA17 was abnormally expressed in cancer tissues, and this expression pattern could be associated with immune cell infiltrations in tumor microenvironments. Clinically, SPA17 not only acted as a potent prognostic factor to predict the clinical outcomes of cancer patients but was also a promising immunotherapy predictive biomarker for cancer patients treated with immune-checkpoint inhibitors (ICIs).

Expression Profile of SPACA5/Spaca5 in Spermatogenesis and Transitional Cell Carcinoma of the Bladder

Overexpression of the ASPM Gene is Associated with Aggressiveness and Poor Outcome in Bladder Cancer.

Pan-cancer analysis: SPAG5 is an immunological and prognostic biomarker for multiple cancers

Expression of PSCA protein in human bladder urothelial cancer and its clinical significance

Sperm Autoantigenic Protein 17 Predicts the Prognosis and the Immunotherapy Response of Cancers: A Pan-Cancer Analysis

Expression Profile of a Novel Germ Cell-Specific Gene, TSCPA, in Mice and Human

Expression and Bioinformatics Analysis of SPACA4 in Human and Mice

The expression of CXCL5 in bladder cancer and its clinical significance

SCARA5 as a downstream factor of PCAT29, inhibits proliferation, migration, and invasion of bladder cancer

Expressions of Prostate Stem Cell Antigen and Oct-4 and Their Clinicopatholgical Significances in Transitional Cell Cancer of Bladder

The Expression and Clinical Significance of ZBTB7 in Transitional Cell Carcinoma of the Bladder.

Predictive Value and Immunological Role of the HSPA5 Gene in Cervical Cancer

Expression of RASSF1A, cyclin D1, Bcl-2 and their significance in transitional cell carcinoma fo bladder

A comprehensive pan-cancer analysis revealing SPAG6 as a novel diagnostic, prognostic and immunological biomarker in tumor

Cancer-testis Antigen Sperm Protein 17 Overexpressed in Endometrial and Cervical Carcinomas

The expression of RASSF1A protein and promoter hypermethylation of RASSF1A gene in bladder transitional cell carcinoma

SPAG5 Promotes Hepatocellular Carcinoma Progression by Downregulating SCARA5 Through Modifying Β-Catenin Degradation

Upregulation of sperm-associated antigen 5 expression in endometrial carcinoma was associated with poor prognosis and immune dysregulation, and promoted cell migration and invasion

Detection of Minichromosome Maintenance 5 Protein in Bladder Carcinoma Tissue and Urine Exfoliate Cells

Expression Of Fas/Fasl And C-Myc In Bladder Cancer And Their Correlation With Tumor Immune Function

Altered γ-catenin expression in bladder transitional cell carcinoma and its implication